Trials / Completed
CompletedNCT04664829
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells From a Mesenchymal-Like to an Epithelial-Like Phenotype
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- National Cancer Centre, Singapore · Academic / Other
- Sex
- Female
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
Triple-negative breast cancer (TNBC) is biologically aggressive and has limited systemic treatment options, often compounded by treatment resistance. Cell state transitions, e.g. epithelial-to-mesenchymal transition (EMT) govern cancer cell behaviour. The investigators hypothesize that by inducing change in cell state change, TNBC cells that have manifested taxane-resistance will be more sensitized to subsequent chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bexarotene | Administered orally once a day. Starting dosage: 200mg/m\^2 |
| DRUG | Capecitabine | Administered orally twice a day. Dosage: 1000mg/m\^2 |
Timeline
- Start date
- 2020-10-01
- Primary completion
- 2025-08-04
- Completion
- 2025-08-04
- First posted
- 2020-12-11
- Last updated
- 2025-09-23
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT04664829. Inclusion in this directory is not an endorsement.